Veterinary Oncology Product Launches: What Predicts Success?

摘要

The veterinary oncology specialty market has experienced a remarkable amount of growth over the last 25-30 years. This has been in part thanks to the availability of new USDA-CVB or FDA-CVM conditional and/ or fully licensed/approved therapeutics overthe last 10 years. This time period is very similar to the late 1990s and early 2000s when an explosion of new human cancer therapeutics were approved by the FDA. In 2017 alone, the FDA approved 16 new drugs for the treatment of human cancer.Over the last 10 years, veterinary oncologists have seen development, rollout and marketing strategies that have worked well and, unfortunately, some that were less successful. The successes and failures often have an origmating central theme around thelevel of data, predominately in the context of efficacy and less about safety. Another variable in this equation is cost, in the context of both development of the therapeutic or diagnostic by the animal health company, as well as cost of that product for purchase by the veterinarian. The interplay of these variables and how veterinary oncologists place these in importance will be discussed below as well as during the lecture.